Cargando…

Pharmacological and dietary-supplement treatments for autism spectrum disorder: a systematic review and network meta-analysis

BACKGROUND: There is still no approved medication for the core symptoms of autism spectrum disorder (ASD). This network meta-analysis investigated pharmacological and dietary-supplement treatments for ASD. METHODS: We searched for randomized-controlled-trials (RCTs) with a minimum duration of seven...

Descripción completa

Detalles Bibliográficos
Autores principales:	Siafis, Spyridon, Çıray, Oğulcan, Wu, Hui, Schneider-Thoma, Johannes, Bighelli, Irene, Krause, Marc, Rodolico, Alessandro, Ceraso, Anna, Deste, Giacomo, Huhn, Maximilian, Fraguas, David, San José Cáceres, Antonia, Mavridis, Dimitris, Charman, Tony, Murphy, Declan G., Parellada, Mara, Arango, Celso, Leucht, Stefan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8896153/ https://www.ncbi.nlm.nih.gov/pubmed/35246237 http://dx.doi.org/10.1186/s13229-022-00488-4

Ejemplares similares

Placebo response in pharmacological and dietary supplement trials of autism spectrum disorder (ASD): systematic review and meta-regression analysis
por: Siafis, Spyridon, et al.
Publicado: (2020)

Imputing the Number of Responders from the Mean and Standard Deviation of CGI-Improvement in Clinical Trials Investigating Medications for Autism Spectrum Disorder
por: Siafis, Spyridon, et al.
Publicado: (2021)

M201. MODERATORS OF WEIGHT GAIN IN RANDOMIZED CONTROLLED TRIALS OF SCHIZOPHRENIA – A META-REGRESSION ANALYSIS
por: Schneider-Thoma, Johannes, et al.
Publicado: (2020)

T200. METABOLIC SIDE EFFECTS OF ANTIPSYCHOTIC DRUGS – PROTOCOL OF A SYSTEMATIC REVIEW AND NETWORK- METAANALYSIS
por: Schneider-Thoma, Johannes, et al.
Publicado: (2020)

Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia
por: Bighelli, Irene, et al.
Publicado: (2022)

Antipsychotic dose reduction compared to dose continuation for people with schizophrenia
por: Rodolico, Alessandro, et al.
Publicado: (2022)

Efficacy of clozapine compared with other second-generation antipsychotic drugs in patients with treatment-resistant schizophrenia: protocol for a systematic review and individual patient data meta-analysis of randomised controlled trials
por: Siafis, Spyridon, et al.
Publicado: (2023)

Metabolic side effects of antipsychotic drugs in individuals with schizophrenia during medium- to long-term treatment: protocol for a systematic review and network meta-analysis of randomized controlled trials
por: Schneider-Thoma, Johannes, et al.
Publicado: (2021)

A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Arbaclofen Administered for the Treatment of Social Function in Children and Adolescents With Autism Spectrum Disorders: Study Protocol for AIMS-2-TRIALS-CT1
por: Parellada, Mara, et al.
Publicado: (2021)

How well do elderly patients with major depressive disorder respond to antidepressants: a systematic review and single-group meta-analysis
por: Gutsmiedl, Katharina, et al.
Publicado: (2020)

Antipsychotic drugs and their effects on cognitive function: protocol for a systematic review, pairwise, and network meta-analysis
por: Feber, Lena, et al.
Publicado: (2023)

Predictors of outcome in early-onset psychosis: a systematic review
por: Díaz-Caneja, Covadonga M, et al.
Publicado: (2015)

S204. REDUCTION OF ANTIPSYCHOTIC DOSES AND POLYPHARMACY: TWO COCHRANE REVIEWS
por: Leucht, Stefan, et al.
Publicado: (2020)

Estimating and visualising the trade-off between benefits and harms on multiple clinical outcomes in network meta-analysis
por: Chiocchia, Virginia, et al.
Publicado: (2023)

Response rates in patients with schizophrenia and positive symptoms receiving cognitive behavioural therapy: a systematic review and single-group meta-analysis
por: Bighelli, Irene, et al.
Publicado: (2018)

Autism with co-occurring epilepsy care pathway in Europe
por: Mendez, Maria A., et al.
Publicado: (2023)

T117. PROMINENT AND PERSISTENT AUTISTIC TRAITS ARE ASSOCIATED WITH EARLY NON-REMISSION IN FIRST-EPISODE SCHIZOPHRENIA
por: Pina-Camacho, Laura, et al.
Publicado: (2020)

Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose-response meta-analysis
por: Siafis, Spyridon, et al.
Publicado: (2023)

F214. PSYCHOLOGICAL INTERVENTIONS FOR POSITIVE SYMPTOMS IN SCHIZOPHRENIA: A NETWORK META-ANALYSIS
por: Bighelli, Irene, et al.
Publicado: (2018)

Psychosocial treatments for relapse prevention in schizophrenia: study protocol for a systematic review and network meta-analysis of randomised evidence
por: Bighelli, Irene, et al.
Publicado: (2020)

Autism care pathway in Europe
por: Mendez, Maria A., et al.
Publicado: (2023)

Evidence-based Shared-Decision-Making Assistant (SDM-assistant) for choosing antipsychotics: protocol of a cluster-randomized trial in hospitalized patients with schizophrenia
por: Siafis, Spyridon, et al.
Publicado: (2022)

Validation of the Glasgow Antipsychotic Side-Effect Scale (GASS) in an Italian Sample of Patients with Stable Schizophrenia and Bipolar Spectrum Disorders
por: Rodolico, Alessandro, et al.
Publicado: (2022)

Effects of antipsychotics on heart rate in treatment of schizophrenia: a systematic review and meta-analysis
por: Huhn, Maximilian, et al.
Publicado: (2022)

Informing the development of a decision aid: Expectations and wishes from service users and psychiatrists towards a decision aid for antipsychotics in the inpatient setting
por: Müller, Katharina, et al.
Publicado: (2023)

Effectiveness of cognitive remediation in schizophrenia: What works and what does not work?
por: Vita, A., et al.
Publicado: (2021)

Pharmacological Treatment of Early-Onset Schizophrenia: A Critical Review, Evidence-Based Clinical Guidance and Unmet Needs
por: Lopez-Morinigo, Javier-David, et al.
Publicado: (2022)

Characterisation of the clinical phenotype in Phelan-McDermid syndrome
por: Burdeus-Olavarrieta, Mónica, et al.
Publicado: (2021)

Efficacy and safety of clozapine in psychotic disorders—a systematic quantitative meta-review
por: Wagner, Elias, et al.
Publicado: (2021)

Psychometric Properties of The Clinician Affective Reactivity Index for Assessment of Irritability in a Clinical Sample of Turkish Children and Adolescents
por: Turan, Serkan, et al.
Publicado: (2022)

Second-to-Fourth Digit Ratio (2D:4D) in Psychiatric Disorders: A Systematic Review of Case-control Studies
por: Fusar-Poli, Laura, et al.
Publicado: (2021)

The impact of COVID-19 lockdown on child and adolescent mental health: systematic review
por: Panchal, Urvashi, et al.
Publicado: (2021)

The Added Value of Liquid Antipsychotics: The Case of Quetiapine
por: Papazisis, Georgios, et al.
Publicado: (2019)

Care pathway for autistic children and their families in Europe
por: Mendez, M.A., et al.
Publicado: (2022)

Oxidative Stress and Inflammation in Early Onset First Episode Psychosis: A Systematic Review and Meta-Analysis
por: Fraguas, David, et al.
Publicado: (2017)

Acceptability of cognitive remediation for schizophrenia: a systematic review and meta-analysis of randomized controlled trials
por: Vita, Antonio, et al.
Publicado: (2023)

Fronto-Parietal Gray Matter Volume Loss Is Associated with Decreased Working Memory Performance in Adolescents with a First Episode of Psychosis
por: Rapado-Castro, Marta, et al.
Publicado: (2021)

How do core autism traits and associated symptoms relate to quality of life? Findings from the Longitudinal European Autism Project
por: Oakley, Bethany FM, et al.
Publicado: (2020)

Effectiveness, Core Elements, and Moderators of Response of Cognitive Remediation for Schizophrenia: A Systematic Review and Meta-analysis of Randomized Clinical Trials
por: Vita, Antonio, et al.
Publicado: (2021)

Tachyphylaxis to the Sedative Action of Mirtazapine
por: Papazisis, Georgios, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_6pqjte7vpa9eaqqjli3s0r7p06